From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Factors | Logistic regression model | |||
---|---|---|---|---|
p value | OR | 95%CI | ||
Lower | Higher | |||
Univariate logistic regression | ||||
Circ-SMARCA5 (high vs low) | 0.049 | 2.597 | 1.006 | 6.707 |
Age (≥60 years vs < 60 years) | 0.278 | 0.603 | 0.242 | 1.502 |
Gender (male vs female) | 0.822 | 0.900 | 0.359 | 2.257 |
Immunoglobulin subtype | ||||
IgG vs others | 0.369 | 1.530 | 0.605 | 3.867 |
IgA vs others | 0.150 | 0.383 | 0.104 | 1.413 |
IgM vs others | 1.000 | 0.000 | 0.000 | – |
IgD vs others | 0.406 | 3.292 | 0.198 | 54.631 |
Bence-Jones protein vs others | 0.777 | 1.179 | 0.378 | 3.674 |
Hb (≥10 g/dL vs < 10 g/dL) | 0.101 | 0.460 | 0.182 | 1.164 |
Calcium ≥11.5 mg/dL vs < 11.5 mg/dL) | 0.391 | 0.620 | 0.208 | 1.848 |
Scr (≥2 mg/dL vs < 2 mg/dL) | 0.484 | 1.441 | 0.517 | 4.014 |
ALB (≥3.5 mg/dL vs < 3.5 mg/dL) | 0.362 | 1.613 | 0.577 | 4.511 |
β2-MG (≥5.5 mg/L vs < 5.5 mg/L) | 0.034 | 0.332 | 0.120 | 0.918 |
LDH (≥220 U/L vs < 220 U/L) | 0.198 | 0.491 | 0.166 | 1.451 |
Durie-Salmon stage (III vs I&II) | 0.233 | 1.743 | 0.700 | 4.343 |
ISS stage (III vs I&II) | 0.034 | 0.332 | 0.120 | 0.918 |
Bone lesion (yes vs no) | 0.942 | 1.038 | 0.382 | 2.816 |
Cytogenetics abnormality | ||||
t (4; 14) translocation (yes vs no) | 0.767 | 0.783 | 0.155 | 3.951 |
t (14; 16) translocation (yes vs no) | 0.709 | 0.773 | 0.200 | 2.991 |
Del (17p) (yes vs no) | 0.377 | 0.493 | 0.103 | 2.368 |
Multivariate logistic regression with Forward Stepwise (Conditional) method | ||||
ISS stage (III vs I&II) | 0.034 | 0.332 | 0.120 | 0.918 |